Blasi Francesco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2110444/publications.pdf

Version: 2024-02-01

236 papers

8,639 citations

42 h-index

66343

80 g-index

242 all docs 242 docs citations

times ranked

242

11536 citing authors

#	Article	IF	Citations
1	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
2	Heated Humidified High-Flow Nasal Oxygen in Adults. Chest, 2015, 148, 253-261.	0.8	317
3	Characterization of Myocardial Injury in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2043-2055.	2.8	303
4	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	6.7	253
5	Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141.	6.7	238
6	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: TableÂ1. Thorax, 2015, 70, 984-989.	5.6	224
7	Management of bronchiectasis in adults. European Respiratory Journal, 2015, 45, 1446-1462.	6.7	220
8	Complement activation in patients with COVID-19: AÂnovel therapeutic target. Journal of Allergy and Clinical Immunology, 2020, 146, 215-217.	2.9	210
9	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 513-521.	3.8	176
10	A review of national guidelines for management of COPD in Europe. European Respiratory Journal, 2016, 47, 625-637.	6.7	145
11	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 2016, 117, 190-197.	2.9	136
12	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	2.6	133
13	Electronic cigarettes: a task force report from the European Respiratory Society. European Respiratory Journal, 2019, 53, 1801151.	6.7	131
14	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
15	Analysis of the DNA-Binding Profile and Function of TALE Homeoproteins Reveals Their Specialization and Specific Interactions with Hox Genes/Proteins. Cell Reports, 2013, 3, 1321-1333.	6.4	125
16	Biochemistry of the tale transcription factors PREP, MEIS, and PBX in vertebrates. Developmental Dynamics, 2014, 243, 59-75.	1.8	125
17	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	5.8	116
18	The Severe Asthma Network in Italy: Findings and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1462-1468.	3.8	112

#	Article	IF	CITATIONS
19	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.8	105
20	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428.	6.7	102
21	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine, the, 2021, 9, 873-884.	10.7	99
22	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Journal of Allergy and Clinical Immunology, 2021, 147, 561-566.e4.	2.9	90
23	Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β–SMAD3 pathway in non-small cell lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3775-84.	7.1	87
24	The urokinase receptor. A cell surface, regulated chemokine. Apmis, 1999, 107, 96-101.	2.0	86
25	Community-acquired pneumonia related to intracellular pathogens. Intensive Care Medicine, 2016, 42, 1374-1386.	8.2	85
26	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	3.5	82
27	The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. PLoS ONE, 2014, 9, e101228.	2.5	79
28	Neutrophil elastase in bronchiectasis. Respiratory Research, 2017, 18, 211.	3.6	75
29	Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. International Journal of Molecular Sciences, 2016, 17, 1913.	4.1	70
30	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respiratory Medicine, the, 2022, 10, 298-306.	10.7	70
31	COVIDâ€19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 887-892.	5.7	69
32	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest, 2017, 151, 47-59.	0.8	59
33	From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. International Journal of Molecular Sciences, 2020, 21, 5882.	4.1	57
34	Prone and Lateral Positioning in Spontaneously Breathing Patients With COVID-19 Pneumonia Undergoing Noninvasive Helmet CPAP Treatment. Chest, 2020, 158, 2431-2435.	0.8	56
35	Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. International Journal of Infectious Diseases, 2014, 18, 14-21.	3.3	55
36	Treatment strategies for asthma: reshaping the concept of asthma management. Allergy, Asthma and Clinical Immunology, 2020, 16, 75.	2.0	55

#	Article	IF	CITATIONS
37	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respiratory Medicine, 2020, 166, 105947.	2.9	55
38	Pulmonary embolism in a young pregnant woman with COVID-19. Thrombosis Research, 2020, 191, 36-37.	1.7	52
39	Bedaquiline and delamanid in tuberculosis. Expert Opinion on Pharmacotherapy, 2015, 16, 2319-2330.	1.8	49
40	A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer. BioEssays, 2017, 39, 1600245.	2.5	48
41	The biology of pulmonary exacerbations in bronchiectasis. European Respiratory Review, 2019, 28, 190055.	7.1	48
42	Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106184.	2.5	48
43	Identification, nucleotide sequence and expression of the regulatory region of the histidine operon of Escherichia coli K-12. Nucleic Acids Research, 1981, 9, 2075-2086.	14.5	46
44	A comprehensive approach to lung function in bronchiectasis. Respiratory Medicine, 2018, 145, 120-129.	2.9	46
45	A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. Chest, 2020, 158, 929-938.	0.8	46
46	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
47	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. European Respiratory Journal, 2018, 51, 1702215.	6.7	45
48	High-flow nasal therapy vs standard oxygen during breaks off noninvasive ventilation for acute respiratory failure: A pilot randomized controlled trial. Journal of Critical Care, 2018, 48, 418-425.	2.2	44
49	Perception of symptoms and quality of life & Derception of patients & Derception of symptoms and physicians & Derception of COPD, 2017, Volume 12, 2189-2196.	2.3	43
50	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	5.6	43
51	The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. European Respiratory Journal, 2020, 56, 2001157.	6.7	43
52	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. Chest, 2018, 154, 798-807.	0.8	42
53	COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 603-604.	1.6	40
54	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	3.6	39

#	Article	IF	Citations
55	Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response. Frontiers in Immunology, 2021, 12, 785941.	4.8	38
56	The absence of i>Prep1 / i>causes p53-dependent apoptosis of mouse pluripotent epiblast cells. Development (Cambridge), 2010, 137, 3393-3403.	2.5	37
57	Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644.	6.7	37
58	Acute exacerbations of COPD: risk factors for failure and relapse. International Journal of COPD, 2017, Volume 12, 2687-2693.	2.3	37
59	Sputum neutrophil elastase associates with microbiota and <i>Pseudomonas aeruginosa</i> in bronchiectasis. European Respiratory Journal, 2020, 56, 2000769.	6.7	37
60	Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. International Journal of COPD, 2015, 10, 1917.	2.3	35
61	Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infectious Diseases, 2015, 15, 78.	2.9	35
62	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	1.3	34
63	Pneumococcal vaccination and chronic respiratory diseases. International Journal of COPD, 2017, Volume 12, 3457-3468.	2.3	34
64	Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infectious Diseases, 2018, 18, 677.	2.9	34
65	Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respiratory Research, 2018, 19, 18.	3.6	34
66	Quality standards for the management of bronchiectasis in Italy: a national audit. European Respiratory Journal, 2016, 48, 244-248.	6.7	33
67	Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. European Respiratory Journal, 2017, 49, 1700076.	6.7	33
68	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. European Respiratory Journal, 2014, 44, 1412-1417.	6.7	32
69	Therapy with protonâ€pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology, 2016, 21, 883-890.	2.3	32
70	Prognostic parameters of inâ€hospital mortality in COVIDâ€19 patients—An Italian experience. European Journal of Clinical Investigation, 2021, 51, e13629.	3.4	31
71	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. Allergy, Asthma and Immunology Research, 2021, 13, 219.	2.9	31
72	Switching treatments in COPD: implications for& nbsp; costs and treatment adherence. International Journal of COPD, 2015, 10, 2601.	2.3	30

#	Article	IF	CITATIONS
73	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	3.5	30
74	Efficacy and safety of TOBI Podhaler in <i>Pseudomonas aeruginosa-</i> iiinfected bronchiectasis patients: iBEST study. European Respiratory Journal, 2021, 57, 2001451.	6.7	30
75	Non-Intensive Care Unit Acquired Pneumonia: A New Clinical Entity?. International Journal of Molecular Sciences, 2016, 17, 287.	4.1	29
76	In vitro activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and biofilm. PLoS ONE, 2018, 13, e0203941.	2.5	29
77	Enzymic Pathway for Thyroxine Synthesis Through p-Hydroxy-3,5-diiodophenylpyruvic Acid. Endocrinology, 1969, 85, 542-551.	2.8	28
78	How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis. International Journal of Molecular Sciences, 2018, 19, 3256.	4.1	28
79	Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study. ERJ Open Research, 2018, 4, 00096-2018.	2.6	28
80	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	4.0	28
81	Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Description (SIMER). Pulmonary Pharmacology and Therapeutics, 2015, 34, 25-30.	2.6	27
82	Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 26.	1.5	27
83	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. European Respiratory Journal, 2019, 53, 1801183.	6.7	27
84	Acute myocardial infarction $\langle i \rangle$ versus $\langle i \rangle$ other cardiovascular events in community-acquired pneumonia. ERJ Open Research, 2015, 1, 00020-2015.	2.6	26
85	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. European Respiratory Journal, 2018, 52, 1802074.	6.7	26
86	An international perspective on hospitalized patients with viral community-acquired pneumonia. European Journal of Internal Medicine, 2019, 60, 54-70.	2.2	26
87	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.8	26
88	The burden of sinus disease in cystic fibrosis lung transplant recipients. Transplant Infectious Disease, 2018, 20, e12924.	1.7	25
89	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine, 2021, 180, 106355.	2.9	25
90	Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. Journal of Cystic Fibrosis, 2022, 21, 111-114.	0.7	25

#	Article	IF	CITATIONS
91	Down syndrome fibroblasts and mouse Prep1-overexpressing cells display increased sensitivity to genotoxic stress. Nucleic Acids Research, 2010, 38, 3595-3604.	14.5	24
92	Pknox1/Prep1 Regulates Mitochondrial Oxidative Phosphorylation Components in Skeletal Muscle. Molecular and Cellular Biology, 2014, 34, 290-298.	2.3	24
93	ChIP-Seq and RNA-Seq Analyses Identify Components of the Wnt and Fgf Signaling Pathways as Prep1 Target Genes in Mouse Embryonic Stem Cells. PLoS ONE, 2015, 10, e0122518.	2.5	24
94	Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials. Respiratory Medicine, 2020, 172, 106127.	2.9	24
95	Tumorigenesis by Meis1 overexpression is accompanied by a change of DNA target-sequence specificity which allows binding to the AP-1 element. Oncotarget, 2015, 6, 25175-25187.	1.8	24
96	Pertussis Toxin B-Oligomer Suppresses IL-6 Induced HIV-1 and Chemokine Expression in Chronically Infected U1 Cells via Inhibition of Activator Protein 1. Journal of Immunology, 2006, 176, 999-1006.	0.8	23
97	Repeteability of Circulating Eosinophil Measures and Inhaled Corticosteroids Effect in Bronchiectasis. A Post Hoc Analysis of a Randomized Clinical Trial. Archivos De Bronconeumologia, 2020, 56, 681-683.	0.8	23
98	Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respiratory Research, 2018, 19, 11.	3.6	22
99	In Vitro Synergism of Colistin and N-acetylcysteine against Stenotrophomonas maltophilia. Antibiotics, 2019, 8, 101.	3.7	22
100	Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. Frontiers in Medicine, 2022, 9, 834354.	2.6	22
101	The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidisciplinary Respiratory Medicine, 2017, 12, 12.	1.5	21
102	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. European Journal of Internal Medicine, 2017, 37, 13-18.	2.2	21
103	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88.	0.7	21
104	Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. Journal of Cystic Fibrosis, 2021, 20, 388-394.	0.7	21
105	Selective localization of receptors for urokinase amino-terminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells. Experimental Cell Research, 1992, 203, 427-434.	2.6	20
106	Exertional Hypoxemia in Stable COPD Is Common and Predicted by Circulating Proadrenomedullin. Chest, 2014, 146, 328-338.	0.8	20
107	Adrenomedullin optimises mortality prediction in COPD patients. Respiratory Medicine, 2015, 109, 734-742.	2.9	20
108	Proteome Investigation of Rat Lungs subjected to Ex Vivo Perfusion (EVLP). Molecules, 2018, 23, 3061.	3.8	20

#	Article	IF	CITATIONS
109	Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology and	2.6	19
110	Differential DNA damage signalling and apoptotic threshold correlate with mouse epiblast-specific hypersensitivity to radiation. Development (Cambridge), 2015, 142, 3675-85.	2.5	19
111	In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms. Journal of Antimicrobial Chemotherapy, 2018, 73, 2388-2395.	3.0	19
112	COVIDâ€19 in lung transplant recipients: A case series from Milan, Italy. Transplant Infectious Disease, 2020, 22, e13356.	1.7	19
113	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. Respiratory Research, 2015, 16, 150.	3.6	18
114	PREP1 tumor suppressor protects the late-replicating DNA by controlling its replication timing and symmetry. Scientific Reports, 2018, 8, 3198.	3.3	18
115	Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respiratory Research, 2018, 19, 205.	3.6	18
116	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. American Journal of Cardiology, 2020, 137, 111-117.	1.6	18
117	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	3.5	18
118	PMA-induced down-regulation of the receptor for $\hat{l}\pm 2$ -macroglobulin in human U937 cells. FEBS Letters, 1995, 358, 73-78.	2.8	17
119	Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. Respiratory Research, 2014, 15, 6.	3.6	17
120	Genuair $\hat{A}^{\text{@}}$ Usability Test: Results of a National Public Survey of the Elderly. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 367-371.	1.6	17
121	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidisciplinary Respiratory Medicine, 2018, 13, 39.	1.5	17
122	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 2943.	2.4	17
123	The most appropriate therapeutic strategy for acute lower respiratory tract infections: a Delphi-based approach. Journal of Chemotherapy, 2017, 29, 274-286.	1.5	16
124	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101855.	2.6	16
125	Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101856.	2.6	16
126	The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. Human Vaccines and Immunotherapeutics, 2020, 16, 340-348.	3.3	16

#	Article	IF	Citations
127	Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: A ten-year cohort study. Respiratory Medicine, 2020, 164, 105899.	2.9	16
128	Does Improving Exercise Capacity and Daily Activity Represent the Holistic Perspective of a New COPD Approach?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 575-581.	1.6	15
129	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. European Respiratory Journal, 2020, 56, 2001702.	6.7	15
130	Early pulmonary function and midâ€term outcome in lung transplantation after exâ€vivo lung perfusion – a singleâ€center, retrospective, observational, cohort study. Transplant International, 2020, 33, 773-785.	1.6	15
131	Amyloid-like Prep1 peptides exhibit reversible blue-green-red fluorescence <i>in vitro</i> and in living cells. Chemical Communications, 2021, 57, 3720-3723.	4.1	15
132	Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Therapeutics and Clinical Risk Management, 2013, 9, 55.	2.0	14
133	Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. Pulmonary Pharmacology and Therapeutics, 2015, 33, 1-10.	2.6	14
134	Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. Clinical and Molecular Allergy, 2021, 19, 5.	1.8	14
135	Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. International Journal of Molecular Sciences, 2022, 23, 977.	4.1	14
136	Interactive Monitoring Service and COPD: Is it Possible to Reduce Nonadherence?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 227-233.	1.6	13
137	Prep1 prevents premature adipogenesis of mesenchymal progenitors. Scientific Reports, 2017, 7, 15573.	3.3	13
138	Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulmonary Pharmacology and Therapeutics, 2017, 45, 191-201.	2.6	13
139	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 50, 28-37.	2.6	13
140	Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. Respiratory Medicine, 2018, 138, 88-94.	2.9	13
141	Prognostic value of copeptin and midâ€regional proadrenomedullin in COVIDâ€19â€hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	3.4	13
142	Role of <i>Streptococcus pneumoniae</i> infection in chronic obstructive pulmonary disease patients in Italy. Therapeutic Advances in Respiratory Disease, 2017, 11, 403-407.	2.6	12
143	IFNÎ 3 /4 locus polymorphisms and IFNÎ 3 circulating levels are associated with COPD severity and outcomes. BMC Pulmonary Medicine, 2018, 18, 51.	2.0	12
144	Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy. Internal and Emergency Medicine, 2021, 16, 1173-1181.	2.0	12

#	Article	lF	CITATIONS
145	Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Current Opinion in Pharmacology, 2021, 57, 81-88.	3.5	12
146	Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series. Journal of Cystic Fibrosis, 2022, 21, 885-887.	0.7	12
147	Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study. Pneumonia (Nathan Qld), 2016, 8, 8.	6.1	11
148	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	6.7	11
149	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	2.6	11
150	Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulmonary Medicine, 2019, 19, 171.	2.0	11
151	Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review. Medical Sciences (Basel, Switzerland), 2019, 7, 10.	2.9	11
152	Intraoperative extracorporeal membrane oxygenation for lung transplantation in cystic fibrosis patients: Predictors and impact on outcome. Journal of Cystic Fibrosis, 2020, 19, 659-665.	0.7	11
153	Clinical Use and Barriers of Thoracic Ultrasound: A Survey of Italian Pulmonologists. Respiration, 2020, 99, 171-176.	2.6	11
154	Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine, 2022, 192, 106728.	2.9	11
155	Therapeutic approach to respiratory infections in lung transplantation. Pulmonary Pharmacology and Therapeutics, 2015, 32, 149-154.	2.6	10
156	Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation. Respiratory Medicine, 2016, 119, 7-12.	2.9	10
157	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	1.5	10
158	Nasopharyngeal Microbiota Analysis in Healthy and Otitis-prone Children. Pediatric Infectious Disease Journal, 2021, 40, 16-21.	2.0	10
159	Efferocytosis: another function of uPAR. Blood, 2009, 114, 752-753.	1.4	9
160	Reduction of Prep1 Levels Affects Differentiation of Normal and Malignant B Cells and Accelerates Myc Driven Lymphomagenesis. PLoS ONE, 2012, 7, e48353.	2.5	9
161	Prep1 (pKnox1) Regulates Mouse Embryonic HSC Cycling and Self-Renewal Affecting the Stat1-Sca1 IFN-Dependent Pathway. PLoS ONE, 2014, 9, e107916.	2.5	9
162	Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection. Multidisciplinary Respiratory Medicine, 2017, 12, 2.	1.5	9

#	Article	IF	Citations
163	An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2017, 18, 973-988.	1.8	9
164	Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide. International Journal of COPD, 2018, Volume 13, 2319-2333.	2.3	9
165	Mapping the native interaction surfaces of PREP1 with PBX1 by cross-linking mass-spectrometry and mutagenesis. Scientific Reports, 2020, 10, 16809.	3.3	9
166	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. Expert Review of Respiratory Medicine, 2021, 15, 419-424.	2.5	9
167	HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5955.	2.4	9
168	The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis. PLoS ONE, 2014, 9, e96711.	2.5	8
169	Purification and Characterization of a DNA-Binding Recombinant PREP1:PBX1 Complex. PLoS ONE, 2015, 10, e0125789.	2.5	8
170	Public awareness on cystic fibrosis: results from a national pragmatic survey. European Respiratory Journal, 2015, 46, 264-267.	6.7	8
171	Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia. Respiratory Research, 2016, 17, 98.	3.6	8
172	When and how ruling out cystic fibrosis in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 29.	1.5	8
173	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology and Therapeutics, 2019, 58, 101834.	2.6	8
174	Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry. Journal of Asthma and Allergy, 2020, Volume 13, 599-604.	3.4	8
175	Manifesto on the Value of Adult Immunization: "We Know, We Intend, We Advocate― Vaccines, 2021, 9, 1232.	4.4	8
176	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research, 2021, 7, 00807-2020.	2.6	8
177	Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. Biomedicines, 2022, 10, 200.	3.2	8
178	Electronic nicotine delivery systems (ENDS): the beginning of the end or the end of the beginning?. European Respiratory Journal, 2014, 44, 585-588.	6.7	7
179	Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 555-560.	1.6	7
180	Serotypes and antibiotic susceptibility of <i>Streptococcus pneumoniae</i> isolated from hospitalized patients with community-acquired pneumonia in Italy. SAGE Open Medicine, 2017, 5, 205031211772005.	1.8	7

#	Article	IF	Citations
181	Lung Diseases: Chronic Respiratory Infections. International Journal of Molecular Sciences, 2018, 19, 3051.	4.1	7
182	The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study. PLoS ONE, 2019, 14, e0221889.	2.5	7
183	Challenges in the Diagnosis and Management of Bacterial Lung Infections in Solid Organ Recipients: A Narrative Review. International Journal of Molecular Sciences, 2020, 21, 1221.	4.1	7
184	Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2920-2922.e2.	3.8	7
185	Diagnostic Value of Endotracheal Aspirates Sonication on Ventilator-Associated Pneumonia Microbiologic Diagnosis. Microorganisms, 2017, 5, 62.	3.6	6
186	Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists. European Respiratory Journal, 2019, 53, 1802209.	6.7	6
187	Immune Checkpoints Expression in Chronic Lung Allograft Rejection. Frontiers in Immunology, 2021, 12, 714132.	4.8	6
188	Laryngotracheal aspiration test reduce the false negative rate in patients with suspected SARS-COV-2 pneumonia despite a negative nasopharyngeal swab. European Journal of Internal Medicine, 2021, 91, 59-62.	2.2	6
189	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. European Respiratory Journal, 2017, 50, 1602306.	6.7	5
190	Impact of bone-active drugs and underlying disease on bone health after lung transplantation: A longitudinal study. Journal of Cystic Fibrosis, 2021, 20, e100-e107.	0.7	5
191	Mucormycosis in CAPA, a Possible Fungal Super-Infection. Journal of Fungi (Basel, Switzerland), 2021, 7, 708.	3.5	5
192	MEIS1 in Hematopoiesis and Cancer. How MEIS1-PBX Interaction Can Be Used in Therapy. Journal of Developmental Biology, 2021, 9, 44.	1.7	5
193	Achoo, achis, ATCHIN! Vaccine you…. European Respiratory Journal, 2018, 51, 1702558.	6.7	4
194	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 48, 111-116.	2.6	4
195	The genetics and the molecular functions of the PREP1 homeodomain transcription factor. International Journal of Developmental Biology, 2018, 62, 819-825.	0.6	4
196	Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1975-1990.	1.8	4
197	Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. Journal of Asthma, 2022, 59, 1908-1913.	1.7	4
198	SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. Journal of Cystic Fibrosis, 2022, 21, e113-e116.	0.7	4

#	Article	IF	Citations
199	Time to active sitting position: One-year findings from a temporary COVID-19 intensive care unit. Respiratory Medicine, 2022, 194, 106773.	2.9	4
200	Lung Biomolecular Profile and Function of Grafts from Donors after Cardiocirculatory Death with Prolonged Donor Warm Ischemia Time. Journal of Clinical Medicine, 2022, 11, 3066.	2.4	4
201	Innovation in lung health research—a Copernican revolution?. Lancet Respiratory Medicine,the, 2013, 1, 506-507.	10.7	3
202	Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. European Journal of Internal Medicine, 2016, 34, 85-88.	2.2	3
203	The Role of Prep1 in the Regulation of Mesenchymal Stromal Cells. International Journal of Molecular Sciences, 2019, 20, 3639.	4.1	3
204	Right Ventricle Dysfunction in Patients With Adult Cystic Fibrosis Enlisted for Lung Transplant. Transplantation Proceedings, 2021, 53, 260-264.	0.6	3
205	Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVIDâ€19?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 961-962.	5.7	3
206	The Isoform GC1f of the Vitamin D Binding Protein Is Associated with Bronchiectasis Severity. Biomedicines, 2021, 9, 1573.	3.2	3
207	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: a SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respiratory Medicine, 2021, 190, 106674.	2.9	3
208	The transcription factor PREP1(PKNOX1) regulates nuclear stiffness, the expression of LINC complex proteins and mechanotransduction. Communications Biology, 2022, 5, 456.	4.4	3
209	Respiratory infections management: Still a challenge. Pulmonary Pharmacology and Therapeutics, 2015, 32, 117-118.	2.6	2
210	Epidemiology of clinical trials of medicines in respiratory diseases in Europe and Italy. Respiratory Medicine, 2017, 125, 8-11.	2.9	2
211	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opinion on Emerging Drugs, 2018, 23, 185-199.	2.4	2
212	Administrative databases and clinical governance: The case of COPD. International Journal of Health Planning and Management, 2019, 34, 177-186.	1.7	2
213	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study., 2020, 2, e0220.		2
214	Early acute rejection after lung transplantation mimicking viral pneumonia in the middle of COVID-19 pandemic: A case report. International Journal of Surgery Case Reports, 2020, 77, 80-85.	0.6	2
215	Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. Respiratory Medicine, 2021, 179, 106341.	2.9	2
216	INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW. Ulster Medical Journal, 2018, 87, 129-130.	0.2	2

#	Article	IF	Citations
217	Risk of a biased assessment of the evidence when limiting literature searches to the English language: Macrolides in asthma as an illustrative example. Pulmonary Pharmacology and Therapeutics, 2015, 31, 109-110.	2.6	1
218	Bronchiectasis in 2016: advances in our understanding. Lancet Respiratory Medicine, the, 2016, 4, 940-941.	10.7	1
219	Uneven distribution of professors and instructors in medical disciplines dealing with the four main chronic non-communicable diseases: the case of the Italian Universities. Multidisciplinary Respiratory Medicine, 2017, 12, 27.	1.5	1
220	The Evaluation of Determinants and Impacts of Co-Production in Healthcare: A Research Protocol for OPAT in Cystic Fibrosis. International Journal of Integrated Care, 2021, 21, 15.	0.2	1
221	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2022, 11, 635-638.	4.0	1
222	Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over. Journal of Cystic Fibrosis, 2022, , .	0.7	1
223	Effect of Chemical Modification of Keratin Structure on Its Electron Spin Resonance Spectrum after Irradiation. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine, 1967, 11, 393-394.	1.0	0
224	Maurizio Luisetti. European Respiratory Journal, 2015, 45, 324-325.	6.7	0
225	Electronic nicotine delivery systems. European Respiratory Journal, 2015, 45, 858.2-859.	6.7	0
226	Each day is a new beginning. Multidisciplinary Respiratory Medicine, 2017, 12, 4.	1.5	0
227	Response. Chest, 2021, 159, 1677-1678.	0.8	0
228	One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational Study. International Journal of COPD, 2021, Volume 16, 1007-1020.	2.3	0
229	Prevalence and serotyping of S. pneumoniae in a large vaccine-naive cohort of adults with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2443-2446.	2.9	0
230	Response. Chest, 2021, 159, 2507-2508.	0.8	0
231	Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study. International Journal of COPD, 2021, Volume 16, 2133-2148.	2.3	0
232	Urokinase-type plasminogen activator receptor. The AFCS-nature Molecule Pages, 0, , .	0.2	0
233	Women's Cardiac Health in 2020: A Systematic Review. Journal of Cardiac Critical Care TSS, 2020, 4, 104-110.	0.1	0
234	TACKLING ANTIMICROBIAL RESISTANCE (AMR) - IN VITRO EFFECT OF SODIUM CHLORIDE ON ANTIBIOTIC SUSCEPTIBILITY IN CLINICAL PSEUDOMONAS AERUGINOSA ISOLATED FROM PATIENTS WITH CYSTIC FIBROSIS (CF). Ulster Medical Journal, 2020, 89, 126-127.	0.2	0

#	Article	IF	CITATIONS
235	Viral Respiratory Infections: From Bench to Bedside. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 735-736.	2.1	0
236	uPAR and Proteases in Mobilization of Hematopoietic Stem Cells. , 2008, , 433-450.		0